High-dose biotin in progressive multiple sclerosis : a prospective study of 86 patients in routine clinical practice

被引：0
|
作者：
Couloume, L. [1 ]
Ory, S. [1 ]
Wiertlewski, S. [1 ]
Laplaud, D. -A. [1 ]
Michel, L. [2 ]
机构：
[1] CHU Nantes, Serv Neurol, Nantes, France
[2] CHU Rennes, Serv Neurol, Rennes, France
来源：
MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EP1717
引用
收藏
页码：969 / 969
页数：1
相关论文
共 50 条
  • [31] MD1003 (High-Dose Biotin) for the treatment of progressive multiple sclerosis: baseline data and results from a cohort of patients included in a early access program
    Brassat, D.
    Hautecoeur, P.
    Durand-Dubief, F.
    Castelnovo, G.
    Derache, N.
    Bourre, B.
    Le Page, E.
    Donze, C.
    Audoin, B.
    Ouallet, J-C.
    Collongues, N.
    Simon, O.
    Brion, G.
    Vermersch, P.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 936 - 937
  • [32] Apparent biochemical thyrotoxicosis due to assay interference by high-dose biotin given for multiple sclerosis
    C. Cusini
    L. Sassi
    G. De Paola
    E. Piantanida
    [J]. Journal of Endocrinological Investigation, 2017, 40 : 889 - 890
  • [33] Apparent biochemical thyrotoxicosis due to assay interference by high-dose biotin given for multiple sclerosis
    Cusini, C.
    Sassi, L.
    De Paola, G.
    Piantanida, E.
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2017, 40 (08): : 889 - 890
  • [34] A prospective evaluation of oral high-dose methylprednisolone for acute exacerbations in multiple sclerosis
    Bosca, I.
    Pascual-Lozano, A.
    Coret, F.
    Casanova, B.
    [J]. MULTIPLE SCLEROSIS, 2006, 12 : S104 - S104
  • [35] Irreversible neurological worsening following high-dose corticosteroids in advanced progressive multiple sclerosis
    Koch, M
    De Keyser, J
    [J]. CLINICAL NEUROPHARMACOLOGY, 2006, 29 (01) : 18 - 19
  • [36] Effect of MD1003 (High-Dose Biotin) in spinal progressive multiple sclerosis (MS-SPI): EDSS sub-scores
    Papeix, C.
    Lebrun-Frenay, C.
    Defer, G.
    Labauge, P.
    Ruiz, M.
    Simon, O.
    Tourbah, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 938 - 939
  • [37] MD1003 (High-Dose Pharmaceutical Biotin) for the Treatment of Progressive Multiple Sclerosis: Baseline Data and Results from an Early Access Program
    Brassat, David
    Hautecoeur, Patrick
    Durand-Dubief, Francoise
    Castelnovo, Giovanni
    Derache, Nathalie
    Bourre, Bertrand
    Donze, Cecile
    Ouallet, Jean-Christophe
    Collongues, Nicolas
    Simon, Olivier
    Brion, Guillaume
    Sedel, Frederic
    Vermersch, Patrick
    Lasser, Robert
    Morteau, Olivier
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 31 - 32
  • [38] IMMUNOSUPPRESSION WITH HIGH-DOSE IV CYCLOPHOSPHAMIDE AND ACTH IN PROGRESSIVE MULTIPLE-SCLEROSIS - CUMULATIVE EXPERIENCE IN 100 PATIENTS
    CARTER, JL
    DAWSON, DM
    FALLIS, RJ
    HAFLER, DA
    STAZZONE, L
    WEINER, HL
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 1987, 16 (01) : 29 - 29
  • [39] High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial
    Schreiber, Karen
    Magyari, Melinda
    Sellebjerg, Finn
    Iversen, Pernille
    Garde, Ellen
    Madsen, Camilla Gobel
    Bornsen, Lars
    Christensen, Jeppe Romme
    Ratzer, Rikke
    Siebner, Hartwig Roman
    Laursen, Bjarne
    Sorensen, Per Soelberg
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (05) : 675 - 685
  • [40] No change in phosphorous magnetic resonance spectroscopy and diffusion tensor imaging in patients with progressive multiple sclerosis treated with high-dose biotin. A one-year follow-up study
    Kauv, P.
    Chalah, M.
    Creange, A.
    Ayache, S.
    Hodel, J.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 516 - 516
12345